Stability, metabolism and transport of D-Asp(OBzl)-Ala -: a model prodrug with affinity for the oligopeptide transporter

被引:17
作者
Steffansen, B
Lepist, EI
Taub, ME
Larsen, BD
Frokjaer, S
Lennernäs, H
机构
[1] Univ Uppsala, Dept Pharm, S-75123 Uppsala, Sweden
[2] Royal Danish Sch Pharm, Dept Pharmaceut, DK-2100 Copenhagen, Denmark
[3] Novo Nordisk AS, DK-2760 Maaloev, Denmark
[4] Royal Vet & Agr Univ, Dept Chem, DK-1871 Copenhagen, Denmark
[5] Tartu State Univ, Inst Pharm, EE-2400 Tartu, Estonia
关键词
oligopeptide transporter; in situ rat perfusion; stability; in vitro metabolism; peptide absorption; model prodrug; Caco-2-model;
D O I
10.1016/S0928-0987(98)00062-1
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The model prodrug D-Asp(OBzl)-Ala has previously been shown to have affinity and to be transported by the oligopeptide transporter PepT(1) expressed in Caco-2 cells. The main objective of the present study was to investigate the aqueous stability of D-Asp(OBzl)-Ala and its in vitro metabolism in different gastrointestinal media arising from rats and humans, as well as in human plasma. The second major aim of the study was to evaluate our previous study in Caco-2 cell culture, by determining the effective intestinal permeability (P-eff) of D-Asp(OBzl)-Ala in situ using the single-pass rat perfusion model. The aqueous stability studies show water, general buffer, as well as specific acid and base catalysis of D-Asp(OBzl)-Ala. The degradation of the model prodrug was independent of ionic strength. The half-lives in rat jejunal fluid and homogenate were >3 h. In human gastric and intestinal fluids, the half-lives were >3 h and 2.3+/-0.03 h, respectively. rising the rat single-pass perfusion technique, the effective jejunal permeability (P-eff) of D-Asp(OBzl)-Ala was determined to be high (1.29+/-0.5.10(-4) cm/s). The 32 times higher P-eff value found in the perfusion model compared to Caco-2 cells is most likely due to a higher functional expression of the oligopeptide transporter. Rat jejuna P-eff was reduced by approximately 50% in the presence of well known oligopeptide transporter substrates, such as Gly-Sar and cephalexin. It may be that D-Asp(OBzl)-Ala is primarily absorbed intact by the rat jejunal oligopeptide transporter, since the stability in the intestinal homogenate and fluids was rather high (t(1/2)>2.3 h). (C) 1999 Elsevier Science BN. All rights reserved.
引用
收藏
页码:67 / 73
页数:7
相关论文
共 35 条
[1]  
Abidi S. A., 1997, GASTROENTEROLOGY, V113, P332
[2]   DISTRIBUTION OF BRUSH-BORDER MEMBRANE PEPTIDASES ALONG THE RAT INTESTINE [J].
BAI, JPF .
PHARMACEUTICAL RESEARCH, 1994, 11 (06) :897-900
[3]   STRUCTURAL SPECIFICITY OF MUCOSAL-CELL TRANSPORT AND METABOLISM OF PEPTIDE DRUGS - IMPLICATION FOR ORAL PEPTIDE DRUG DELIVERY [J].
BAI, JPF ;
AMIDON, GL .
PHARMACEUTICAL RESEARCH, 1992, 9 (08) :969-978
[4]   UTILIZATION OF PEPTIDE CARRIER SYSTEM TO IMPROVE INTESTINAL-ABSORPTION - TARGETING PROLIDASE AS A PRODRUG-CONVERTING ENZYME [J].
BAI, JPF ;
HU, M ;
SUBRAMANIAN, P ;
MOSBERG, HI ;
AMIDON, GL .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1992, 81 (02) :113-116
[5]   PGLU-L-DOPA-PRO - A TRIPEPTIDE PRODRUG TARGETING THE INTESTINAL PEPTIDE TRANSPORTER FOR ABSORPTION AND TISSUE ENZYMES FOR CONVERSION [J].
BAI, JPF .
PHARMACEUTICAL RESEARCH, 1995, 12 (07) :1101-1104
[6]   STRUCTURAL REQUIREMENTS FOR THE INTESTINAL MUCOSAL-CELL PEPTIDE TRANSPORTER - THE NEED FOR N-TERMINAL ALPHA-AMINO GROUP [J].
BAI, PF ;
SUBRAMANIAN, P ;
MOSBERG, HI ;
AMIDON, GL .
PHARMACEUTICAL RESEARCH, 1991, 8 (05) :593-599
[7]   Influence of proton and essential histidyl residues on the transport kinetics of the H+/peptide cotransport systems in intestine (PEPT 1) and kidney (PEPT 2) [J].
Brandsch, M ;
Brandsch, C ;
Ganapathy, ME ;
Chew, CS ;
Ganapathy, V ;
Leibach, FH .
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 1997, 1324 (02) :251-262
[8]  
Caldwell GW, 1998, J MASS SPECTROM, V33, P607, DOI 10.1002/(SICI)1096-9888(199807)33:7<607::AID-JMS672>3.0.CO
[9]  
2-O
[10]   Comparison between permeability coefficients in rat and human jejunum [J].
Fagerholm, U ;
Johansson, M ;
Lennernas, H .
PHARMACEUTICAL RESEARCH, 1996, 13 (09) :1336-1342